Disclaimer: This article is based on actual news from the real world – honestly! However, it has been sprinkled with a healthy dose of satire.
KILCHBERG, Switzerland — Swiss chocolate company Lindt & Sprüngli announced Tuesday that Americans taking GLP-1 weight-loss drugs are buying chocolate at a faster rate than the general population, a finding that defied every forecast, several medical assumptions, and at least one of Newton’s laws of thermodynamics.
Chocolate probably doesn't even cause weight gain, right? (Rosinka79/depositphotos)
The company cited an internal study based on data from market researcher Circana, which found that while GLP-1 households represent 15% of the U.S. population, they account for 17.5% of chocolate sales. Premium chocolate purchases among GLP-1 users rose nearly 17% in 2025, compared to 6.5% among people whose relationship with food remains unmedicated.
“They are upgrading to premium products,” CEO Adalbert Lechner told reporters in Kilchberg, delivering the line with the serene confidence of a man whose product just beat a billion-dollar drug class in a head-to-head trial of human weakness. Lindt did not comment on what this means for the concept of willpower as a virtue, but the earnings call is on Thursday.
The food industry’s broader response to GLP-1 drugs has followed the five classic stages of corporate grief: denial, reformulation, rebranding, smaller packaging, and calling it “innovation.” General Mills CEO Jeff Harmening acknowledged the drugs would have a “lasting influence” on the food market, then announced Honey Nut Cheerios Protein, a product that sounds like a cereal having an identity crisis in a GNC parking lot.
Nestlé launched Vital Pursuit, its first major U.S. brand in thirty years, and a name that suggests someone in marketing briefly considered “Desperate Measures” before legal stepped in. Because nothing says “responding to a paradigm shift in human metabolism” like naming your frozen meals after a Tom Clancy subtitle. Danone rolled out a yogurt drink for GLP-1 users designed to help people “build and retain muscle mass,” which is technically a health claim and spiritually a surrender document. Conagra began labeling some Healthy Choice frozen meals “GLP-1 friendly,” a phrase that did not exist eighteen months ago and now appears on packaging next to a picture of steamed broccoli.
Bob Nolan, Conagra’s Senior Vice President of Demand Science, a title that is apparently real even though it sounds like it was inspired by a Black Mirror spec script, explained that if they can attract consumers while they’re on the drugs, those consumers are likely to stick around even after they stop taking those drugs. A study found that 50% to 75% of GLP-1 users quit within a year, which Nolan appears to view less as a public health data point and more as a customer retention opportunity. He did not comment on the eerie similarity between his strategy and giving heroin to a chainsmoker, which suggests that, although Conagra is no longer owned by a cigarette company, they may have learned a thing or two from the experience.
Somebody enjoys tearing up newspapers. (zimmytws/depositphotos)
Not everyone is worried. Dirk Van de Put, CEO of Mondelēz International, maker of Oreos, said GLP-1s would have a “minimal” effect on his company’s business. Even with oral medications on the way, he said, there is no indication that “that’s going to change in a substantial way.” He did not elaborate on whether this confidence was based on data, faith, or the molecular structure of Oreos coincidentally (or not) redesigned soon after Nabisco was purchased by R.J. Reynolds in the 1980s. This is the confidence of a man who has spent thirty years watching people try in vain to stop eating Oreos and knows how this ends.
Looking ahead, Lechner said European regulatory approvals would produce similar buying patterns, essentially betting that appetite suppression is no match for the chocolate traditions of nations that put chocolate on bread for breakfast. The commercial implication is clear: a larger pool of customers who eat slightly less of everything except the thing they shouldn’t, purchased at a higher price point. Science tried.
This story is based on fully factual news, but if we got it wrong, blame these guys, we’re just here to make it funny.
